Global Buccal Drug Delivery Systems Market was valued at USD 2.87 billion in 2021 and projected to grow at a CAGR of 9.80% during the forecast period 2022-2028 : Greyviews
14 avr. 2022 05h55 HE
|
GreyViews
Pune, India, April 14, 2022 (GLOBE NEWSWIRE) -- Global Buccal Drug Delivery Systems Market was valued at USD 2.87 billion in 2021 and projected to grow at a CAGR of 9.80% during the forecast period...
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages Investors to Contact the Firm
14 févr. 2022 12h20 HE
|
Bragar Eagel & Squire
NEW YORK, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
28 août 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences Named to the Russell 3000® Index
20 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
10 avr. 2019 16h06 HE
|
BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
21 févr. 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
08 nov. 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29 oct. 2018 08h30 HE
|
BioDelivery Sciences International, Inc.
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 ...
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
25 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
10 sept. 2018 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living...